Forma Therapeutics and Paradigm entered a multiyear strategic partnership to identify predictive response markers and measure pharmacodynamic activity for two of Forma’s advanced preclinical candidates. FORMA said working with Paradigm to assess the potential of molecular markers to predict clinical outcomes will help accelerate clinical decisions and optimize its new medicines for patients.
“Forma’s strategy is to pair a thorough understanding of the molecular drivers of tumor growth and survival with our capability to discover ultra-selective drugs against these qualified targets,” said Steven Tregay, Ph.D., president and CEO, Forma. “Our collaboration with Paradigm enables us to efficiently match our drugs with high quality molecular assays to realize a personalized approach to cancer drug development.”
“Forma has a strong oncology pipeline with many exciting therapeutic candidates,” said Robert Penny, M.D., Ph.D., CEO, Paradigm. “We are excited to be working with Forma to provide greater insights into their programs and trials with our unique expertise and ability to provide genomic information that can impact clinical treatment decisions. Together, we expect to enable a more individualized, targeted approach to cancer drug development and clinical trials.”
In April, Forma and Celgene agreed to expand a collaboration to evaluate emerging families of targets for new drugs, with Celgene accessing Forma’s drug-discovery platforms and network of academic experts.